Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry

被引:15
|
作者
Matsuo, Ryu [1 ,2 ]
Kamouchi, Masahiro [2 ,3 ]
Fukuda, Haruhisa [2 ,3 ]
Hata, Jun [1 ,3 ]
Wakisaka, Yoshinobu [1 ]
Kuroda, Junya [1 ]
Ago, Tetsuro [1 ]
Kitazono, Takanari [1 ,3 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Fukuoka 812, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Hlth Care Adm & Management, Fukuoka 812, Japan
[3] Kyushu Univ, Grad Sch Med Sci, Ctr Cohort Studies, Fukuoka 812, Japan
来源
PLOS ONE | 2014年 / 9卷 / 10期
关键词
RT-PA; TRIAL IST-3; MANAGEMENT; GREATER-THAN-OR-EQUAL-TO-80; ALTEPLASE; TPA;
D O I
10.1371/journal.pone.0110444
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objectives: The benefit of intravenous recombinant tissue plasminogen activator (rt-PA) therapy for very old patients with acute ischemic stroke remains unclear. The aim of this study was to elucidate the efficacy and safety of intravenous rt-PA therapy for patients over 80 years old. Methods: Of 13,521 stroke patients registered in the Fukuoka Stroke Registry in Japan from June 1999 to February 2013, 953 ischemic stroke patients who were over 80 years old, hospitalized within 3 h of onset, and not treated with endovascular therapy were included in this study. Among them, 153 patients were treated with intravenous rt-PA (0.6 mg/kg). For propensity score (PS)-matched case-control analysis, 148 patients treated with rt-PA and 148 PS-matched patients without rt-PA therapy were selected by 1:1 matching with propensity for using rt-PA. Clinical outcomes were neurological improvement, good functional outcome at discharge, in-hospital mortality, and hemorrhagic complications (any intracranial hemorrhage [ICH], symptomatic ICH, and gastrointestinal bleeding). Results: In the full cohort of 953 patients, rt-PA use was associated positively with neurological improvement and good functional outcome, and negatively with in-hospital mortality after adjustment for multiple confounding factors. In PS-matched case-control analysis, patients treated with rt-PA were still at lower risk for unfavorable clinical outcomes than non-treated patients (neurological improvement, odds ratio 2.67, 95% confidence interval 1.61-4.40; good functional outcome, odds ratio 2.23, 95% confidence interval 1.16-4.29; in-hospital mortality, odds ratio 0.30, 95% confidence interval 0.13-0.65). There was no significant association between rt-PA use and risk of hemorrhagic complications in the full and PS-matched cohorts. Conclusions: Intravenous rt-PA therapy was associated with improved clinical outcomes without significant increase in risk of hemorrhagic complications in very old patients (aged. 80 years) with acute ischemic stroke.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis in a Patient with Acute Ischemic Stroke Secondary to Aortic Dissection
    Hong, Keun-Sik
    Park, So-Young
    Whang, Seon-Il
    Seo, So-Young
    Lee, Dong-Ha
    Kim, Han-Joon
    Cho, Joong-Yang
    Cho, Yong-Jin
    Jang, Woo-Ik
    Kim, Chang Young
    JOURNAL OF CLINICAL NEUROLOGY, 2009, 5 (01): : 49 - 52
  • [22] Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI
    Schellinger, PD
    Jansen, O
    Fiebach, JB
    Heiland, S
    Steiner, T
    Schwab, SF
    Pohlers, O
    Ryssel, H
    Sartor, K
    Hacke, W
    STROKE, 2000, 31 (06) : 1318 - 1328
  • [23] Intravenous Thrombolysis With Low-Dose Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Response
    Toyoda, Kazunori
    Koga, Masatoshi
    Minematsu, Kazuo
    STROKE, 2010, 41 (03) : E165 - E165
  • [24] Effect of standardized nursing cooperation on intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke
    Yin, Chunhong
    Qi, Li
    Jing, Xia
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (10): : 11925 - 11931
  • [25] Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with apixaban
    De Smedt, Ann
    Cambron, Melissa
    Nieboer, Koenraad
    Moens, Maarten
    Van Hooff, Robbert-Jan
    Yperzeele, Laetitia
    Jochmans, Kristin
    De Keyser, Jacques
    Brouns, Raf
    INTERNATIONAL JOURNAL OF STROKE, 2014, 9 (07) : E31 - E31
  • [26] Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Dabigatran
    De Smedt, Ann
    De Raedt, Sylvie
    Nieboer, Koenraad
    De Keyser, Jacques
    Brouns, Raf
    CEREBROVASCULAR DISEASES, 2010, 30 (05) : 533 - 534
  • [27] Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older - The tPA Stroke Survey Experience
    Tanne, D
    Gorman, MJ
    Bates, VE
    Kasner, SE
    Scott, P
    Verro, P
    Binder, JR
    Dayno, JM
    Schultz, LR
    Levine, SR
    STROKE, 2000, 31 (02) : 370 - 375
  • [28] Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Rivaroxaban
    Ishihara, Hideyuki
    Torii, Hiroaki
    Imoto, Hirochika
    Oka, Fumiaki
    Sadahiro, Hirokazu
    Suzuki, Michiyasu
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2014, 23 (10): : E457 - E459
  • [29] Intravenous thrombolysis in acute ischemic stroke: Preliminary experience with tissue plasminogen activator
    Cruz-Flores, S
    Thompson, DW
    Banet, G
    Burch, CM
    Parks, BJ
    Selhorst, JB
    Shulman, S
    NEUROLOGY, 1998, 50 (04) : A113 - A114
  • [30] Intravenous recombinant tissue plasminogen activator for acute stroke in Poland: an analysis based on the Safe Implementation of Thrombolysis in Stroke (SITS) Registry
    Kobayashi, A.
    Czlonkowska, A.
    Ahmed, N.
    Romanowicz, S.
    Glonek, M.
    Nyka, W. M.
    Opala, G.
    Wahlgren, N.
    ACTA NEUROLOGICA SCANDINAVICA, 2010, 122 (04): : 229 - 236